Beyond the pill: new medication delivery options for ADHD

Author:

Cutler Andrew J.,Mattingly Gregory W.

Abstract

Successful treatment of pediatric disorders has necessitated the development of alternative medication formulations, as children may prefer alternative dosage forms to tablets or capsules. This is especially true for attention-deficit/hyperactivity disorder (ADHD), which is one of the most common chronic pediatric conditions and often involves children with a variety of overlapping physical, psychological, or neurodevelopmental disorders. A special challenge for developing alternative dosage forms for ADHD treatment is the incorporation of a once-daily long-acting formulation. Traditional ADHD medication formulations have been limited, and issues surrounding prescribed dosing regimens—including poor medication adherence, difficulty swallowing, and the lack of dosing titration options—persist in ADHD treatment. In other disease areas, the development of alternative formulations has provided options for patients who have issues with consuming solid dosage forms, particularly children and individuals with developmental disorders. In the light of these new developments, several alternative formulations for ADHD medications are under development or have recently become available. This article reviews the various strategies for developing alternative dosage forms in other disease areas and discusses the application of these strategies in ADHD treatment. Alternative dosage forms may increase medication adherence, compliance, and patient preference and, therefore, improve the overall treatment for ADHD.

Publisher

Cambridge University Press (CUP)

Subject

Psychiatry and Mental health,Neurology (clinical)

Reference123 articles.

1. Procentra® Dextroamphetamine Sulfate Oral Solution, CII Full Prescribing Information. Independence Pharmaceuticals LLC, Newport, KY; 2015.

2. Zenzedi® Dextroamphetamine Sulfate Tablets, CII Full Prescribing Information. Arbor Pharmaceuticals LLC, Atlanta, GA; 2014.

3. Concerta® (Methylphenidate HCl) Extended-Release Tablets, CII full Prescribing Information. Janssen Pharmaceuticals Inc., Titusville, NJ; 2015.

4. Evekeo™ (Amphetamine Sulfate Tablets, USP), CII Full Prescribing Information. Arbor Pharmaceuticals LLC, Atlanta, GA; 2015.

5. Focalin® Dexmethylphenidate Hydrochloride Tablets, CII Full Prescribing Information. Novartis Pharmaceuticals Corporation, East Hanover, NJ; 2013.

Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3